All articles by admin 

  1. Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

    Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock. The Irish biopharmaceutical…
    Read More…

    21 Sep
  2. Cavion starts enrolment in Phase II trial of CX-8998 for essential tremor

    US-based biotechnology firm Cavion has started patient enrolment in a Phase II clinical trial (T-CALM Study) of CX-8998 to treat…
    Read More…

    21 Sep
  3. Audentes commences dosing in Phase I/II trial for myotubular myopathy

    US-based biotechnology firm Audentes Therapeutics has commenced patient dosing in the Phase I/II ASPIRO clinical trial of its product candidate…
    Read More…

    21 Sep
  4. Shire reports positive data from Phase III trial of Intuniv for ADHD

    Irish biotechnology firm Shire and its Japanese partner Shionogi have reported positive top-line results from a Phase III clinical trial…
    Read More…

    21 Sep
  5. Transgene starts dosing in Phase Ib/II combination trial for HPV-positive cancers

    Transgene has started dosing patients in a Phase Ib/II clinical trial of TG4001 in combination with avelumab to treat human…
    Read More…

    20 Sep
  6. AgeneBio to study AGB101 in Phase III trial to treat MCI due to AD

    US-based pharmaceutical firm AgeneBio is set to investigate its therapeutic agent AGB101 in a Phase III clinical trial (HOPE4MCI) for…
    Read More…

    20 Sep
  7. Parker Institute begins dosing in Phase Ib/II combination trial for pancreatic cancer

    The Parker Institute for Cancer Immunotherapy and Cancer Research Institute in the US have started dosing patients in a Phase…
    Read More…

    20 Sep
  8. Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL

    US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen…
    Read More…

    19 Sep
  9. Cytokinetics begins dosing omecamtiv mecarbil in Phase III cardiovascular trial

    Cytokinetics has begun dosing patients in Japan in a Phase III cardiovascular outcomes clinical trial (GALACTIC-HF) of omecamtiv mecarbil as…
    Read More…

    19 Sep
  10. Janssen reports positive long-term Phase III data of Tremfya for plaque psoriasis

    Janssen Research & Development has reported new positive two-year results from the open-label extension of the Phase III VOYAGE 1…
    Read More…

    19 Sep